
Available online at www.sciencedirect.com

Brain Research Reviews 45 (2004) 196–212

Review

GABA transporters in the mammalian cerebral cortex:  
localization, development and pathological implications

Fiorenzo Conti*, Andrea Minelli†, Marcello Melone

Dipartimento di Neuroscienze, Sezione di Fisiologia, Università Politecnica delle Marche, Via Tronto 10/A, Torrette di Ancona, I-60020 Ancona, Italy

Accepted 9 March 2004  
Available online 14 May 2004

---

### Abstract

The extracellular levels of γ-aminobutyric acid (GABA), the main inhibitory neurotransmitter in the mammalian cerebral cortex, are regulated by specific high-affinity, Na⁺/Cl⁻ dependent transporters. Four distinct genes encoding GABA transporters (GATs), named GAT-1, GAT-2, GAT-3, and BGT-1 have been identified using molecular cloning. Of these, GAT-1 and -3 are expressed in the cerebral cortex. Studies of the cortical distribution, cellular localization, ontogeny and relationships of GATs with GABA-releasing elements using a variety of light and electron microscopic immunocytochemical techniques have shown that: (i) a fraction of GATs is strategically placed to mediate GABA uptake at fast inhibitory synapses, terminating GABA’s action and shaping inhibitory postsynaptic responses; (ii) another fraction may participate in functions such as the regulation of GABA’s diffusion to neighboring synapses and of GABA levels in cerebrospinal fluid; (iii) GATs may play a role in the complex processes regulating cortical maturation; and (iv) GATs may contribute to the dysregulation of neuronal excitability that accompanies at least two major human diseases: epilepsy and ischemia.

© 2004 Elsevier B.V. All rights reserved.

---

### Theme: D  
### Topic: GABA  

### Keywords: Amino acid neurotransmitters; Neurotransmitter uptake; Neurons; Glia; Inhibitory synapses

---

### Contents

1. **Introduction** . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
F. Conti et al. / Brain Research Reviews 45 (2004) 196–212

5. Comments and conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Fig. 1. Distribution of GAT-1 (A), GAT-2 (B), and GAT-3 (C) ir in three adjacent sections of SI cortex in an adult rat [28]. The thionine-stained section (D) is adjacent to those illustrated in A–C; roman numerals indicate cortical layers. The section in E shows the distribution of GAD₆₇ ir. (A–C) Sections processed using polyclonal antibodies to GATs obtained from Dr. N.C. Brecha (Dept. of Neurobiol., UCLA, USA) and characterized in previous papers [40,105,142,143]. (E) Section processed using the antiGAD₆₇ antibody characterized by Kaufman et al. [112] and purchased from Chemicon (Temecula, CA, USA). Bar: 100 μm for A–E.

46; see Ref. [26]), they display a homogeneous distribution [39]. Comparative analysis of the laminar patterns of GAT-1+ puncta in rat, monkey and humans indicated that the pattern of GAT-1 expression is related to cortical type rather than to species [39]. In all species, GAT-1+ fibers are also present in the white matter underlying the neocortex and are especially numerous in the corpus callosum of rats [39,142].

In all the species studied to date, GAT-1+ puncta have a preferential relationship to the soma and proximal dendrites of cortical neurons [39,47,142]. In layers II–III and V–VI, numerous GAT-1+ puncta are observed around the somata and the proximal portions of the apical dendrites of pyramidal cells (Fig. 2A). In most cases, they distinctly outline unlabeled pyramidal cells, although they are also found around nonpyramidal neurons. The patterns of distribution of GAD₆₇+ and GAT-1+ puncta are remarkably similar (Fig. 1; see Refs. [39,142]), as is their relationship to neuronal perikarya and proximal dendrites. Analysis of sections double-labeled with GAT-1 and GABA or GFAP antibodies revealed that the vast majority of GAT-1+ puncta are GABA-positive (Fig. 3) and GFAP-negative (Fig. 2 in Ref. [30]).

The ultrastructural pattern of GAT-1 labeling is similar in all layers of rat, monkey and human cortex [39,142,168]. GAT-1 ir is in axonal and glial profiles (Fig. 2B), whereas somata and dendrites are unlabeled. Axonal labeling is always intense and scattered throughout the axoplasm of thinly myelinated axons and in numerous presynaptic axon terminals forming symmetric synaptic contacts with unlabeled cell bodies or dendrites of all sizes (Fig. 2B). Studies of knock-in mice carrying GAT-1-green fluorescent protein fusions yielded an estimated density of 800–1300 GAT-1 molecules/presynaptic bouton [32]. GAT-1 ir is also found in distal astrocytic processes scattered in the neuropil, sometimes close to GAT-1+ terminals [39,142] (Fig. 2B); this finding is in line with electrophysiological evidence showing the presence of GAT-1-mediated currents in neocortical astrocytes [114].

The cell types giving rise to GAT-1+ puncta have not been determined to date, with a notable exception. Heavily stained GAT-1+ swellings, mostly in layers II–III and VI, are typically aligned in vertically oriented rows below the somata of unlabeled neurons (see Fig. 6C and D in Refs. [39,47]),

Fig. 2. Localization of GAT-1 (A, B), GAT-2 (C, D, E), and GAT-3 (F, G) ir in cerebral cortex and neighboring structures. (A) GAT-1+ puncta outline unlabeled pyramidal neurons in layer III of rat SI (F. Conti, A. Minelli, and M. Melone, unpublished material). (B) GAT-1 is localized to axon terminals forming symmetric synapses (arrowheads) and to a distal astrocytic process (asterisk) (human cerebral cortex; from [39]). (C–E) GAT-2 ir is prominent in leptomeninges and arachnoid trabeculae (C), around blood vessels (D), and in the epithelial cells of the choroid plexus (E) of rat brain (C and D from: F. Conti, A. Minelli, and M. Melone, unpublished material); E, from Ref. [40]. (F) GAT-3+ puncta outline unlabeled neurons in layer V of rat SI (F. Conti, A. Minelli, and M. Melone, unpublished material). (G) A GAT-3+ distal astrocytic process (asterisk) in the vicinity of an axon terminal forming a symmetric synapse (arrowheads) (from Ref. [143]). AxT, axon terminal; Den, dendrite; BV blood vessel; L, leptomeninges; N, nucleus. Scale bars: 10 μm for A and F, 0.5 μm for B; 20 μm for C and D, 15 μm for E; and 0.25 μm for G.

thus displaying a pattern similar to that of GABAergic chandelier axon terminals [48,161]: these GAT-1+ puncta coexpress parvalbumin [47], a Ca²⁺-binding protein expressed by chandelier cells [50], thus indicating that chandelier cells give rise to some GAT-1+ puncta. In addition, the strong perisomatic labeling of pyramidal cells suggests that basket cells also contribute GAT-1+ puncta [196].

### 2.2. GAT-2

Although in vitro investigations showed high levels of GAT-2 mRNA in some astrocytes [23], early in situ hybridization and immunocytochemical studies failed to detect GAT-2 in brain parenchyma, and reported that it is exclusively expressed in leptomeningeal and ependymal cells

[63,100]. This view has partly been challenged by the demonstration that, beside its strong localization to the leptomeninges—where it is detected in the arachnoid and along the thin arachnoid trabeculae in the subarachnoid space—and to ependymal and choroid plexus (Fig. 2C,E), GAT-2 ir is also present in the cortical parenchyma [40]. In SI cortex, faint GAT-2 ir is found in puncta, cell bodies and processes [40]. GAT-2+ puncta different sizes are scattered in all cortical layers (Fig. 1B) with no apparent laminar segregation; they are localized to glia limitans (Fig. 2C) and outline blood vessels (Fig. 2D) and unlabeled cell bodies. Rare GAT-2+ cells of both neuronal and glial morphology are present in the cortical parenchyma, subcortical white matter and corpus callosum. Scattered GAT-2+ processes are found in the cortical neuropil; of these, some are GFAP+ [40]. However, several GAT-2+ puncta and cell bodies are negative for GFAP [40].

At the ultrastructural level, GAT-2 ir is present in neuronal and non-neuronal cortical cells [40]. Labeled neuronal profiles include perikarya, dendrites and axon terminals, and, occasionally, small myelinated axons. Labeled axon terminals form both asymmetric and symmetric synapses preferentially with distal dendrites and spines. Non-neuronal elements in the cortical parenchyma are astrocytic cell bodies and their proximal and distal processes; the latter, which form perivascular end-feet, are scattered throughout the cortical neuropil, sometimes close to unlabeled terminals with symmetric or asymmetric specializations, but often in areas unrelated to synaptic terminals. GAT-2 ir is also found in astrocytic processes forming glia limitans, in leptomeningal cells and their processes, in the ependymal cells lining the third ventricle, and in choroid plexus epithelial cells [40].

### 2.3. GAT-3

Contrary to the results of early investigations [34,63, 100], GAT-3 ir is not negligible in the cerebral cortex [143] (Fig. 1C). In rat cerebral cortex, GAT-3 ir is localized exclusively to small punctate structures (Fig. 2F) that are difficult to resolve at the light microscope and never appears as labeled fibers or cell bodies [63,100,143]. The highest level of GAT-3 ir is observed in layer IV and in a narrow band corresponding to lower layer V, followed by layers II, III and IV and VI [143] (Fig. 1C). Small patches of tissue exhibiting less intense GAT-3 ir are also found in all cortical layers (Fig. 1C), particularly in layers VI and IV [143]. GAT-3+ puncta form a continuous sheet around the somata of both pyramidal and nonpyramidal neurons in all layers (Fig. 2F). In layers II–III and V, they are also closely associated with the proximal portion of basal and apical dendrites of pyramidal cells. GAT-3+ puncta are more numerous in the neuropil and are generally smaller than the majority of GAT-1+ puncta [143] (compare Figs. 2A and F).

GAT-3 labeling is found exclusively in distal astrocytic processes (Fig. 2G), whereas astrocytic cell bodies and neuronal profiles are always unlabeled [143]. Like those immunoreactive for GAT-1 and GAT-2, GAT-3+ astrocytic processes form perivascular end-feet and are adjacent to axon terminals making either symmetric (Fig. 2G) or asymmetric synaptic contacts with cell bodies or dendrites, or are close to neuronal profiles that do not form synaptic contacts in the plane of section [143].

In surgical samples of human cerebral cortex, GAT-3 ir is found throughout its depth in puncta as well as neurons [139]. GAT-3+ puncta are both dispersed in the neuropil and closely associated with cell bodies, forming a continuous sheet around the somata of both pyramidal and nonpyramidal neurons. Neuronal staining is mostly in perikarya and proximal dendrites of pyramidal neurons; the density of GAT-3+ neurons is variable and unrelated to cortical area. Electron microscopic studies showed GAT-3 ir both in distal astrocytic processes and in neurons and their processes. Since surgical resection induces an acute ischemic situation in the resected sample [111], GAT-3+ neurons may actually not be expressed in humans in physiological conditions. This view is sustained by reports that all GAT-3+ neurons express heat shock protein 70 (HSP70) and that they are numerous in cortical samples from rat cortex resected and processed like human surgical samples [139], and it is reinforced by the detection of GAT-3 ir in rat cortical neurons following transient focal cerebral ischemia [140] (see Section 4.2.). These data could indicate a similar localization of GAT-3 in human and rat cortex, and that GAT-3 is more susceptible than GAT-1 to changes in the energy supply.

### 2.4. Relationship of GATS to GABAergic synapses

Despite some species differences [94], the GABAergic system appears to obey a basic organizational plan in which GABAergic neurons are most numerous in layers II–III and IV, followed by layer VI, while GABAergic axon terminals are densest in layers IV and II–III, moderately dense in layers I and VI, and least dense in layer Va [89,94,106,115, 173,194]. The laminar distribution of GAT-1+ and GAT-3+ puncta is therefore strikingly similar to that of GABA-releasing axon terminals (Fig. 1), suggesting that GATs are most expressed in the layers where GABA is released. The vast majority of axon terminals forming symmetric synapses on pyramidal and nonpyramidal neocortical neurons arise from several types of GABAergic nonpyramidal cells (including smooth and sparsely spinous neurons with local plexus axons and basket, chandelier and double-bouquet cells) and all GABAergic axon terminals form symmetric synapses [46,88,94,106,115,173,195]. The findings that the vast majority of GAT-1+ (and rare GAT-2+) puncta are axon terminals forming symmetric synapses [39,40,142], and that few GAT-2+ [40] and some GAT-3+ puncta are astrocytic processes located in the vicinity of

Fig. 3. Most GAT-1+ puncta contain GABA. Single plane confocal images from layer III of rat SI cortex showing that GAT-1 (green)- and GABA (red)-immunoreactive profiles have similar distribution and morphology. Merged image shows a prominent overlap of the two signals (for details on image acquisition and processing, see Refs. [144,145]). Scale bar: 5 μm.

symmetric synapses [143], support the notion of an intimate relationship between GABAergic synapses and GATs. Added to the demonstration that GAT-1+ axon terminals contain GABA (Fig. 3) and that GAT-2+ and GAT-3+ astrocytic processes are located near GABAergic axon terminals [40,143], these data lead to the surmise that GATs located in the vicinity of symmetric synapses are responsible for GABA uptake at inhibitory synapses, thus contributing to terminating GABA’s synaptic action and to shaping inhibitory postsynaptic responses in the cerebral cortex [30] (Fig. 4). An electrophysiological study of GABAergic transmission in GAT-1-knock-out mouse hippocampus supports this view and suggests that elevated GABA levels resulting from GAT-1 deficiency may induce post- and presynaptic changes in GABAergic synapses [104].

However, this hypothesis needs to be considered in the light of other data, which do not indicate that the distribution of GATs is coextensive with that of GABAergic synapses; in fact, some GAT-1 is localized to distal astrocytic processes scattered in the neuropil [39,142], GAT-2 is mostly located in neuronal and glial processes that are distant from synapses [40], and a fraction of GAT-3+ puncta is not close to symmetric synapses but at asymmetric, glutamatergic [49] synapses [143]. Nor does all the evidence agree with the view that GATs are located and operate exclusively at GABAergic synapses. Overall, data rather seem to point to a widespread system of GABA uptake in the mammalian cerebral cortex that is more extensive than

the GABA-releasing system. This second component of the cortical GABA uptake system is hardly suited to interfere with classic (point-to-point) inhibitory synapses³ and is probably to be thought of in terms of one of the forms of interneuronal communication that have been ascertained on functional grounds; indeed, classic neurotransmitters such as GABA, glutamate and glycine also produce changes at some distance from their sites of release [2,10,101,102,120, 121,177,209]. Although GABA spillover has not been directly demonstrated in mammalian neocortex, but only in the hippocampus [102,153,180,209], cerebellum [58,60, 87,146,177] and retina [99], it is conceivable that the function of cortical GATs located at extrasynaptic sites is to regulate the diffusion of the GABA that mediates the cross-talk between neighboring and/or distant synapses

³ Although Sherrington [187], who introduced the term, viewed the synapse as a physiological concept [185,188] encompassing much of the variety of interactions known at present [186], for the last 50 years this term has been used almost exclusively to indicate the interneuronal junction described by early electronmicroscopists in the mid-1950s [57,158,159]. Since the vast majority of modern localizational and electrophysiological studies use the term synapse in this anatomical acceptance, we have conformed to this usage. The term is therefore used here to indicate “a presynaptic element containing synaptic vesicles and an apposed postsynaptic element from which it is separated by an intercellular space, the synaptic cleft, 10 to 20 nm wide” [162]. Accordingly, the adjective extrasynaptic is used to indicate an element participating in interneuronal chemical communication located at a distance from a synapse.

F. Conti et al. / Brain Research Reviews 45 (2004) 196–212

![Diagram](attachment:diagram.png)

Fig. 4. Highly schematic representation of the localization of GATs at cortical synapses. GAT-1 is shown in blue, GAT-2 in red, and GAT-3 in yellow. Modified from Ref. [30].

[39,142,143]. The slow time course of astrocytic GATs currents recorded in neocortical astrocytes [114] supports this view.

Finally, a third, discrete fraction of GATs is found at sites where it can interact with the cerebrospinal fluid (CSF). This fraction appears to be constituted exclusively of GAT-2 expressed by leptomeninges, ependymal and choroid plexus cells [40,63,100,169]. Although not specific for the cerebral cortex, this fraction may be capable of modifying cortical neuronal activity by sensing local CSF composition [54,150] and regulating GABA transport through the blood-brain barrier [5,109].

Why are there multiple populations of GATs (i.e., of GABA uptake mechanisms) in the cerebral cortex? In heterologous cell systems, GATs exhibit different ionic dependencies (e.g., external Cl⁻) and inhibitor sensitivities [19,82, 83]. In addition, they are subject to regulatory mechanisms affecting both their kinetics and density at synapses [127]: these mechanisms depend on substrate concentration [15,167,212], are coupled to factors controlling transmitter release [52,53,167] and hormone levels [90] and may display regional selectivity [90]. Regulatory mechanisms may exert differential, or even opposite effects on different GATs; for instance, pH alterations affect GAT-3 more than that of GAT-1 [82], and protein kinase C activators increase GABA uptake in cells transfected with GAT-1 [42], but reduce GABA transport in primary astrocyte cultures [77]. Furthermore, GATs may also release GABA into the extracellular space in a Ca²⁺-independent, nonvesicular manner at least in vitro [8, 128,164,183,189,217] (see also Ref. [103] for data on the olfactory bulb) and, given their functional heterogeneity, different GATs may well exhibit different reversal profiles.

It thus appears that the different responses of GATs to the composition of the extracellular milieu, the different regulation of their activity and/or expression, and the possibility of reversing (differentially?) the direction of GABA transport concur to endow the extensive and complex GABA transport system operating in the neocortex with considerable flexibility for the fine regulation of GABA extracellular levels in various physiological and pathological conditions.

## 3. Localization of GATs in the developing cerebral cortex

### 3.1. GAT-1

GAT-1 mRNA and protein first appear at late embryonic stages; their expression, weak in the neonatal cortex, gradually increases in the first two postnatal weeks [66,107,145, 219,222]. Before birth, GAT-1 ir is restricted to the marginal zone (with the exception of the entorhinal cortex, where it is diffuse) [107]. At birth, GAT-1 ir is strong in outer layer I and light in the subplate. At P2, the signal increases in layer V and in the lower cortical plate, whereas the upper cortical plate (i.e., the prospective layers II and III) stains faintly. By P5, ir has extended to the entire cortex, with the highest level in layer I and a band of intense labeling occupying layer IV and the differentiating layer III (Fig. 5A). From P10 onward, GAT-1 ir gradually decreases in layer I and increases in all the other layers, most notably in supragranular ones. The mature pattern of expression is reached by P30 [222]. At all ages, GAT-1 ir is prevalently associated with dot-like structures that are distributed in the neuropil during the first postnatal week (Fig. 6A,B) and at later stages aggregate around unstained neuronal profiles, often forming pericellular basket-like structures [222]. Most GAT-1+ puncta are axon terminals, some of which form symmetric synaptic contacts with unlabeled dendrites (Fig. 6C) or with somata in the early phases of development (see Ref. [222]; A. Minelli, P. Barbaresi, and F. Conti, unpublished observations). GAT-1 is also expressed in astrocytic somata and processes (Fig. 6C), in perivascular glia and, transiently, in the somata and dendrites of GABAergic neurons [222].

Fig. 5. Distribution of GAT-1 (A), GAT-2 (B), and GAT-3 (C) ir in three adjacent sections of developing SI cortex (P5). The thionine-stained section (F) is adjacent to those illustrated in A–D; roman numerals indicate cortical layers. The section in D illustrates the distribution of VGAT, the one in E shows the distribution of GABA ir (P5). (A–C) Sections processed using the antibodies and procedures referred to in the legend to Fig. 1. (D and E) Sections processed using the antiVGAT (D) and the antiGABA (E) antibodies characterized, respectively, by Chaudry et al. [29] and Matute and Streit [135]. Bar: 100 μm for A–E.

GAT-1 mRNA levels increase earlier than those of the protein: at P1, mRNA is 28% of adult levels and between P10 and P30 it exceeds them by 25–40% [219], whereas protein expression is 10.2% of adult levels at birth, it increases at P2 (24.7%), P5 (41%), and P10 (84.2%), it reaches adult levels at P15 (101%), and peaks above them at P30 (119%) [145]. The transient overexpression of GAT-1 in neuronal and astrocytic cell bodies [222] and the peak above adult levels of GAT-1 mRNA and protein at intermediate and late phases of cortical maturation [85,145,219,222] agree with previous findings that in the developing cortex GABA uptake transiently exceeds adult levels [16,33,43,92,170,172,216] and $V_{\text{max}}$ of transport exhibits a parallel trend [43,216].

GAT-1 expression has been studied also in developing human and monkey cortex [65,85]. In human temporal cortex, GAT-1+ puncta appear in the marginal zone at gestational week (GW) 33, they are found in all layers with a density similar to that of the adult by GW 38–39, and attain the mature distribution pattern 1–5 months after birth, when their density exceeds adult levels [85]. Human and rodent cortex thus share a similar spatial pattern of GAT-1 expression during cortical development; in man, however, this expression is anticipated, probably reflecting a corresponding advance of synaptogenesis, which begins early prenatally and peaks a few months after birth [97,98]. In primates, most neocortical synaptogenesis takes place in the embryonic period [24,25,80,225], possibly accounting for the lack of significant changes in the density of GAT-1+ puncta reported in monkey prefrontal cortex during postnatal development [65].

### 3.2. GAT-2

In the rodent brain, GAT-2 mRNA and protein are mainly expressed in the pia-arachnoid membrane and along the arachnoid trabeculae throughout embryonic and postnatal development [66,108,144] (Figs. 5B and 6D). At all ages, parenchymal labeling is weak and uniformly distributed through the cortical wall [144] (Fig. 5B). GAT-2 is robustly expressed by astrocytic processes surrounding blood vessels [108,144], particularly in the early phases of development (Figs. 5B and 6E), when the entire caliber of blood vessels may be completely filled with GAT-2 ir [144]. GAT-2 is also expressed in puncta of various sizes distributed in the neuropil, some of which coexpress synaptophysin [144] (Fig. 6F). At later stages, labeling around blood vessels shrinks to a thin rim [66,144]. From P10 to P15, GAT-2 is also expressed in a small number of astrocytic and neuronal

F. Conti et al. / Brain Research Reviews 45 (2004) 196–212

3.3. GAT-3

GAT-3 expression appears in the marginal and intermediate zones of the cerebral cortex in late embryonic life [66,107], when GAT-3 ir is intense in fasciculate radial structures [107]. GAT-3 mRNA and protein expression increase rapidly in the neonatal brain and until the second postnatal week, when protein expression (which remains relatively stable thereafter [107,144]) diverges from that of mRNA (which decreases) [66].

In neonatal cortex, GAT-3 ir is present throughout the cortical wall in fasciculate structures, in puncta scattered in the neuropil, around blood vessels [107,144], and in numerous cells [144] (Figs. 5C and 6G). In many cases, GAT-3+ cells have an astrocytic morphology (Fig. 6G), and express GFAP [144]. Ultrastructural studies showed GAT-3 to be localized to astrocytic somata, perivascular glial processes and radial glial fibers (Fig. 6H). Colocalization studies also showed that at P2–P5 numerous GABAergic neurons and fibers contain GAT-3 ir and some GAT-3+ puncta coexpress synaptophysin. Electron microscopic studies suggest that about 30% of cortical neurons and many axon terminals and dendritic profiles express GAT-3 [144] (Fig. 6I–J). During the second postnatal week, GAT-3 increases in layer IV and supragranular layers; staining increases in the neuropil, it decreases in astrocytic cell bodies and disappears in neurons [144]. From P15 onward, GAT-3 ir displays the mature pattern of expression [143,144].

3.4. GATs and the development of GABAergic synapses

In rodents, neocortical inhibitory synaptogenesis is a protracted process that begins in late embryonic life and matures through the first postnatal month [18,51,141] (see Fig. 7). GAT-1 maturation follows the same spatial order as inhibitory synaptogenesis and slightly precedes the full establishment of the morphological features of symmetric synapses [145,222], suggesting a role for GAT-1-mediated GABA transport in the formation and maturation of cortical GABAergic synapses. Since GAT-1 is expressed in axon terminals, it is conceivable that it may modulate GABA concentration in the vicinity of nascent synapses. GABA itself regulates the expression and functional properties of GABA<sub>A</sub> receptors [14,75,116,154,155] and chloride transporter KCC2 [14,75,154], whose appearance correlates with the onset of GABA’s inhibitory action [96,176,210]. GAT-1-mediated transport may thus contribute to the maturation of point-to-point GABAergic synapses. In this connection, it is worth stressing that in both rodent and human development GAT-1 expression is coordinated with that of other GABAergic presynaptic proteins, i.e., the synthesizing enzyme GAD [85,215] (see Fig. 7) and the vesicular transporter VGAT [145] (see Fig. 7), and parallels that of the α1 subunit of GABA<sub>A</sub> receptor [72,125], which participates in mature GABAergic transmission.

Fig. 6. Localization of GAT-1 (A–C), GAT-2 (D–F), and GAT-3 (G–J) ir in developing SI cortex (P2–P10). (A and B) GAT-1+ puncta and fibers in layers V–VI (P5) (F. Conti, A. Minelli, and M. Melone, unpublished material). (C) GAT-1 is localized to axon terminals forming symmetric synapses (arrowheads) and to distal astrocytic processes (arrow) (P10; P. Barbaresi, A. Minelli, and F. Conti, unpublished material). (D and E) At P5, GAT-2 ir is prominent in leptomeninges (D), and around blood vessels (E, here shown in a section processed simultaneously for the visualization of GAT-2 (green) and GFAP (red); from Ref. [144]). (F) Some GAT-2+ puncta (green) colocalize synaptophysin (red) (white arrows; from Ref. [144]). (G) GAT-3+ astrocytes in layer V of developing SI (P2; F. Conti, A. Minelli, and M. Melone, unpublished material). (H) A GAT-3+ radial glial fiber (P5; from Ref. [144]). (I and J) GAT-3 ir is also in axon terminals (I) and in dendrites (J; the one illustrated here receives an asymmetric synapse [arrowheads] from an unlabeled axon terminal) (P5; from Ref. [144]). AsP, astrocytic process; AxT, axon terminal; BV blood vessel; Den, dendrite; L, leptomeninges; N, nucleus; RF, radial glial fiber. Scale bars: 10 μm for A, B, and G; 30 μm for D and E; 5 μm for C, H, I, and J.

Notwithstanding largely immature inhibitory synaptogenesis and vesicular mechanisms for GABA storage and release [18,51,141,145], GABAergic neurons are numerous in neonatal cortex [35,55,208] and endogenous GABA levels are relatively high [43] (see Fig. 7). At this stage, GABA is excitatory [31] and acts in a paracrine mode [56,149,154,155,157] as a trophic factor, influencing several morphogenetic aspects of neuronal maturation [13,123,124, 131] via receptor-mediated mechanisms (see Ref. [131,156,197] for data on cerebral cortex). In the neonatal cortex, the only GAT abundantly expressed is GAT-3 [66,144] and GABA uptake is potently inhibited by β-alanine [216], suggesting that extracellular GABA levels at birth are modulated mainly by GAT-3-mediated transport. Since GAT-3 is intensely expressed in the very layers where $GABA_{A}$ receptors are densest (i.e., outer laminae and cortical plate; see Ref. [72,165,166]), it may be involved in modulating GABA’s trophic action.

A currently debated issue regards the sources of non-synaptic GABA release in early brain development. Growth cones arising from GABAergic neurons have been hypothesized to release GABA via reversal transporter activity [9,154,203,204]. Although inhibition of GAT-1-mediated transport does not affect GABA clearance in neonatal hippocampus [56], other transporters, i.e., GAT-3, might be involved, especially in neonatal cortex, where GAT-3 expression far outstrips that of the other GATs. Whereas in the adult neocortex GAT-3 is expressed exclusively in astrocytes [143], at perinatal ages it is also found in a large fraction of cortical GABAergic neurons [144], suggesting that they might release GABA via GAT-3-mediated reversal transport.

Given the scarce neuronal and astrocytic expression of GAT-2 throughout development [66,108,144], its effect on GABA-mediated responses, if any, appears of minor import. The main function of GAT-2 in developing cortex seems to relate to the regulation of GABA levels in CSF and of GABA transport across the blood–brain barrier. Interestingly, the GAT-2+ astrocytic processes surrounding blood vessels are denser in neonatal than adult cortex [108,144], a finding that lends support to recent data showing a faster rate of GABA uptake in immature compared with adult rat brain due, at least partly, to greater maximal transport [5]. Notably, GAT-3+ puncta also surround neonatal cortex blood vessels [144], possibly contributing to effective GABA transport in the neonatal brain and to regulating the amount of neurotrophic GABA available to proliferating and migrating neurons during pre- and perinatal development [154].

### 4. Expression of GATs in neurological diseases

This section does not address all the neuropsychiatric diseases in which changes in GABA transport have been described or could play a role. Rather, it is a succinct

Fig. 7. Highly schematic representation of the postnatal maturation of GATs and other GABAergic markers in rodent cerebral cortex. Data are from: Ref. [145] (GAT-1 and VGAT; immunoblots); A. Minelli, and F. Conti (GAT-2 and GAT-3; gray values; unpublished results); Refs. [51,141] (inhibitory synaptogenesis; density of symmetric synapses); Refs. [43,216] (GAD activity); Ref. [43] (endogenous GABA levels). All data are given as percentage of adult values. *The data on GABA levels are from the whole brain.

overview of the data linking the cortical expression of GATs to the few conditions in which such a role appears likely.

### 4.1. Epilepsy

An increase in GAT-1+ interneurons has been reported in rat neocortex 24 h after corticotropin-releasing hormone-induced seizures [152] and a transient increase in GAT-3 mRNA (but not protein) expression has been described in amygdala-kindled rats 1 h after the last seizure [91].⁴ These findings suggest that seizure activity is associated with an upregulation of neocortical GATs expression. Recent data showing that transgenic mice overexpressing GAT-1 exhibit increased susceptibility to chemically induced seizures, although they do not display spontaneous seizure activity [95], and that enhanced GAT-1-mediated GABA transport is associated with seizures in genetically epileptic mouse strain [73] support this possibility.

Evidence for a downregulation of GATs function in the epileptic neocortex has also been reported: (i) cortical GABA uptake is reduced in different genetic mouse and rat models of epilepsy [41,201]; (ii) GAT-1 mRNA expression is reduced in the neocortex of genetically epilepsy-prone rats [3]; and (iii) GAT-1 is reduced, particularly in perisomatic axon terminals, in the sensorimotor cortex of a rat pilocarpine model of temporal lobe epilepsy [191]. Finally, GAT-1 is reduced and abnormally distributed in the neocortex of patients with temporal lobe epilepsy and focal dysplasia [199].

Interpreting these studies is difficult since they employ different models (which may involve different pathophysiological mechanisms with different temporal patterns) and, most importantly, given the inherent difficulty of isolating primary modifications of GATs expression from secondary, adaptive changes. Increased GATs expression should lower extracellular GABA levels, thus contributing to the origin and spread of epileptic activity; in line with this view, selective GAT-1 blockers (i.e., tiagabine and NNC-711; for reviews see Refs. [1,126,132,137,138,198]) and glial (possibly GAT-3-mediated) GABA uptake inhibitors (i.e., SNAP-5114, NNC 05-2045 and *N*-methyl-exo-THPO; [44,74,79,163,178,182,211]) have been shown to possess anticonvulsant activity. Alternatively, since GABA transporters can work in reverse [8,103,128,164,183,189,217], an upregulation of GATs following sustained neuronal activity may induce a compensatory increase of GABA release via a nonvesicular, transporter-mediated mechanism [62,76,218]. Similarly, the substantial reduction in perisomatic GAT-1+ terminals reported in epileptic neocortex [191] (see also Ref. [6,179] for the hippocampus) is in line with the notions that loss of the GABAAergic cells innervat-

---

⁴ In line with these findings, compounds not acting preferentially on GAT-1 and selective astroglial GATs inhibitors possess significant anticonvulsant activity in chemically and sound-induced seizures [44,74,79,163,178,182,211].

ing the soma and initial axon segment of pyramidal neurons, i.e., basket and chandelier cells [71], is crucial to seizure onset [45,174,175,192,193], but that the reduction of GABA transport and GATs expression may represent a compensatory response homeostatically modulating neuronal overexcitation [198]. Moreover, reduced GATs expression in epileptic tissue may exacerbate epileptiform activity by decreasing the scope for GABA heterotransport [62,76,160].

### 4.2. Ischemia

Following reports that GABA uptake inhibitors tiagabine and NCC-711 exert neuroprotective effects [151,220,223], the cortical expression of GAT-1 and GAT-3 was investigated in a rat model of transient focal ischemia [140]. The study showed that, unlike GAT-1 expression, GAT-3 expression is markedly and selectively affected by ischemia: (i) GAT-3+ puncta (i.e., distal astrocytic processes) are reduced in the perilesional cortex; and (ii) numerous cortical neurons, the vast majority of which are pyramidal, become GAT-3+, particularly in the perilesional cortex; these neurons are not apoptotic (GAT-3+ neurons are TUNEL negative) and express HSP70.

These observations agree with the notion that ischemia induces hyperexcitability in rat neocortex and that in the perilesional cortex neuronal hyperexcitability is, at least partly, determined by reduced GABAAergic activity [61,86, 133,147,181,214]. Since the novel expression of GAT-3 is mostly detected in perikarya of cortical pyramidal neurons, which are important targets of GABAAergic action, an increase in GAT-3 molecules at postsynaptic sites may conceivably increase GABA uptake, thereby reducing the amount of GABA available for binding to receptors and increasing neuronal excitability.

A known physiological instance of cortical neurons expressing GAT-3 is early development [145] (see Sections 3.3 and 3.4), thus indicating that during ischemia GAT-3 expression undergoes a reversion to its immature pattern. Reactivation of embryonic gene expression patterns may occur in the brain after injury-induced hypoxia (for review, see Ref. [113]). Although neuronal GAT-3 in ischemic brain may serve different functions and have different consequences for the organism than in developing neocortex, it is tempting to speculate that it may be part of a genetic “reprogramming” occurring as a response to injury.

### 5. Comments and conclusions

Given its crucial role in the normal functioning of the cerebral cortex, an enormous research effort has been directed in the past decades at investigating GABAAergic transmission. Most studies have focused on pre- and postsynaptic factors (in particular, GABA receptors), generating a vast body of data on their role in information

processing and in the pathophysiology (and in some cases, the therapy) of human diseases. GATs studies are lagging behind, despite their obvious importance in cortical physiology (GATs contribute to shaping inhibition in intracortical circuits as well as to modulating cortical output). The data reviewed here suggest the existence in the cerebral cortex of a complex and heterogeneous system mediating GABA uptake that may have the potential for sustaining the sophisticated adaptive mechanisms allowing the normal functioning of the cortical GABAergic system. Similarly, the complex and asynchronous maturation patterns of GATs revealed in the developing neocortex suggest that GABA transport may contribute both to the cascade of events leading to inhibitory synaptogenesis and to neuronal maturation during early cortical development. Overall, although many details are still missing, the anatomy of the cortical uptake system in both the adult and the developing cerebral cortex appears to be sufficiently understood to allow the study of its dynamic physiological features.

The studies of the expression of GATs in epilepsy and cerebral ischemia (or in their animal models) do not provide definite answers on whether the changes observed have pathophysiological implications. Nevertheless, they show that these changes are compatible with a role for GATs in brain dysfunctions that are either intrinsic features of the pathophysiology of the disease (i.e., epilepsy) or are responsible for the genesis of some of its symptoms (i.e., cerebral ischemia). Besides fostering further research into the involvement of GATs in human diseases, we hope that these preliminary data will promote the development of a larger set of specific agonists and antagonists for use both at the bench and in the therapeutic armamentarium.

## Acknowledgements

We wish to thank all the colleagues who participated in the studies cited in the references for their fundamental contributions, Nick Brecha for introducing us to the field and for the GAT antibodies, Javier DeFelipe for his helpful comments on an early version of this paper, Robert Edwards for the VGAT antibodies, and Carlos Matute for the GABA antibodies. Personal work described here was supported by funds from MIUR (COFIN97, COFIN99, COFIN01) to F.C.

## References

[1] J.C. Adkins, S. Noble, Tiagabine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy, Drugs 55 (1998) 463–470.

[2] S. Ahmadi, U. Muth-Selbach, A. Lauterbach, P. Lipfert, W.L. Neuhuber, H.U. Zeilhofer, Facilitation of spinal NMDA receptor currents by spillover of synaptically released glycine, Science 300 (2002) 2094–2097.

[3] M.T. Akbar, M. Rattray, R.J. Williams, N.W.S. Chong, B.S. Meldrum, Reduction of GABA and glutamate transporter messenger RNAs in the severe-seizure genetically epilepsy-prone rat, Neuroscience 85 (1998) 1235–1251.

[4] K. Albus, P. Wahle, J. Lubke, C. Matute, The contribution of GABAergic neurons to horizontal intrinsic connections in upper layers of the cat’s striate cortex, Exp. Brain Res. 85 (1991) 235–239.

[5] H. Al-Sarraf, Transport of ${}^{14}$C-γ-aminobutyric acid into brain, cerebrospinal fluid and choroid plexus in neonatal and adult rats, Dev. Brain Res. 139 (2002) 121–129.

[6] J.I. Arellano, A. Munoz, I. Ballesteros-Yanez, R.G. Sola, J. DeFelipe, Histopathology and reorganization of chandelier cells in the human epileptic sclerotic hippocampus, Brain 127 (2003) 45–64.

[7] A. Artola, W. Singer, Long-term potentiation and NMDA receptors in rat visual cortex, Nature 330 (1987) 649–652.

[8] D. Attwell, B. Barbour, M. Szatkowski, Nonvesicular release of neurotransmitters, Neuron 11 (1993) 401–407.

[9] V.J. Balcar, I. Dammasch, J.R. Wolff, Is there a non-synaptic component in the $K^+$-stimulated release of GABA in the developing rat cortex? Dev. Brain Res. 10 (1983) 309–311.

[10] B. Barbour, M. Hausser, Intersynaptic diffusion of neurotransmitters, Trends Neurosci. 20 (1997) 377–384.

[11] C. Beaulieu, Numerical data on neurons in adult rat neocortex with special reference to the GABA population, Brain Res. 609 (1993) 284–292.

[12] C. Beaulieu, G. Campistron, C. Crevier, Quantitative aspects of the GABA circuitry in the primary visual cortex of the adult rat, J. Comp. Neurol. 339 (1994) 559–572.

[13] T.N. Behar, A.E. Schaffner, C.A. Colton, R. Somogyi, Z. Olah, C. Lehel, J.L. Barker, GABA-induced chemokinesis and NGF-induced chemotaxis of embryonic spinal cord neurons, J. Neurosci. 14 (1994) 29–38.

[14] Y. Ben-Ari, Excitatory actions of GABA during development: the nature of the nurture, Nat. Rev., Neurosci. 3 (2002) 728–739.

[15] E.M. Bernstein, M.W. Quick, Regulation of gamma-aminobutyric acid (GABA) transporters by extracellular GABA, J. Biol. Chem. 27 (1999) 889–895.

[16] R.D. Blakely, J.A. Clark, T. Pacholczyk, S.G. Amara, Distinct, developmentally regulated brain mRNAs direct the synthesis of neurotransmitter transporters, J. Neurochem. 56 (1991) 860–871.

[17] M. Blatow, A. Rozov, I. Katona, S.G. Hormuzdi, A.H. Meyer, M.A. Whittington, A. Caputi, H. Monyer, A novel network of multipolar bursting interneurons generates theta frequency oscillations in neocortex, Neuron 38 (2003) 805–817.

[18] M.E. Blue, J.C. Parnavelas, The formation and maturation of synapses in the visual cortex of the rat: II. Quantitative analysis, J. Neurocytol. 12 (1983) 697–712.

[19] L.A. Borden, GABA transporter heterogeneity: pharmacology and cellular localization, Neurochem. Int. 29 (1996) 335–356.

[20] L.A. Borden, K.E. Smith, P.R. Hartig, T.A. Brancheck, R.L. Weinshank, Molecular heterogeneity of the γ-aminobutyric acid (GABA) transport system, J. Biol. Chem. 267 (1992) 21098–21104.

[21] L.A. Borden, T.G.M. Dhar, K.E. Smith, T.A. Brancheck, C. Gluchowskic, R.L. Weinshank, Cloning of the human homologue of the GABA transporter GAT-3 and identification of a novel inhibitor with selectivity for this site, Recept. Channels 2 (1994) 207–213.

[22] L.A. Borden, K.E. Smith, E.L. Gustafson, T.A. Brancheck, R.L. Weinshank, Cloning and expression of a betaine/GABA transporter from human brain, J. Neurochem. 64 (1995) 977–984.

[23] L.A. Borden, K.E. Smith, P.J.-J. Vaysse, E.L. Gustafson, R.L. Weinshank, T.A. Brancheck, Re-evaluation of GABA transport in neuronal and glial cultures: correlation of pharmacology and mRNA localization, Recept. Channels 3 (1995) 129–146.

[24] J.P. Bourgeois, Synaptogenesis, heterochrony and epigenesis in the mammalian neocortex, Acta Paediatr., Suppl. 422 (1997) 27–33.

[25] J.P. Bourgeois, P. Rakic, Changes of synaptic density in the primary visual cortex of the macaque monkey from fetal to adult stage, J. Neurosci. 13 (1993) 2801–2820.

[26] K. Brodmann, Vergleichende Lokalisationslehre der Grosshirnrinde

in ihren Prinzipien dargestellt auf Grund des Zellenbaues (Translated and edited by L.J. Garey: “Localization in the cerebral cortex”) Smith-Gordon, London, 1994.

[27] G. Buzsaki, J.J. Chrobak, Temporal structure in spatially organized neuronal assemblies: a role for interneuronal networks, Curr. Opin. Neurobiol. 5 (1995) 504–510.

[28] K. Chapin, C.S. Lin, The somatic sensory cortex of rat, in: B. Kolb, R.G. Tees (Eds.), The Cerebral Cortex of the Rat, MIT Press, Cambridge, 1990, pp. 341–380.

[29] F.A. Chaudry, R.J. Reimer, E.E. Bellocchio, N.C. Dambolt, K.K. Osen, R.H. Edwards, J. Storm-Mathisen, The vesicular GABA transporter, VGAT, localizes to synaptic vesicles in sets of glycinergic as well as GABAergic neurons, J. Neurosci. 18 (1998) 9733–9750.

[30] E. Cherubini, F. Conti, Generating diversity at GABAergic synapses, Trends Neurosci. 24 (2001) 155–162.

[31] E. Cherubini, J.L. Gaiarsa, Y. Ben-Ari, GABA: an excitatory transmitter in early postnatal life, Trends Neurosci. 14 (1991) 515–519.

[32] C.-S. Chiu, K. Jensen, I. Sokolova, D. Wang, M. Li, P. Deshpande, N. Davidson, I. Mody, M.W. Quick, S.R. Quake, H. Lester, Number, density and surface/cyttoplasmic distribution of GABA transporters at presynaptic structures of knock-in mice carrying GABA transporter subtype 1-green fluorescent protein fusions, J. Neurosci. 22 (2002) 10251–10266.

[33] B. Chronwall, J.R. Wolff, Prenatal and postnatal development of GABA-accumulating cells in the occipital neocortex of rat, J. Comp. Neurol. 190 (1980) 187–208.

[34] J.A. Clark, A.Y. Deutch, P.Z. Gallipoli, S. Amara, Functional expression and CNS distribution of a β-alanine-sensitive neuronal GABA transporter, Neuron 9 (1992) 337–348.

[35] A. Cobas, A. Fairen, G. Alvarez-Bolado, M.P. Sanchez, Prenatal development of the intrinsic neurons of the rat neocortex: a comparative study of the distribution of GABA-immunoreactive cells and the GABAA receptor, Neuroscience 40 (1991) 375–397.

[36] F. Conti, T. Manzoni, The neurotransmitters and postsynaptic actions of callosally projecting neurons, Behav. Brain Res. 64 (1994) 37–53.

[37] F. Conti, A. Rustioni, P. Petrusz, A.C. Towle, Glutamate-positive neurons in the somatic sensory cortex of rats and monkeys, J. Neurosci. 7 (1987) 1887–1901.

[38] F. Conti, J. DeFelipe, I. Farinas, T. Manzoni, Glutamate-positive neurons and axon terminals in cat somatosensory cortex: a correlative light and electron microscopic study, J. Comp. Neurol. 290 (1989) 141–153.

[39] F. Conti, M. Melone, S. De Biasi, A. Minelli, N.C. Brecha, A. Ducati, Neuronal and glial localization of GAT-1, a high-affinity GABA plasma membrane transporter, in human cerebral cortex: with a note on its distribution in monkey cortex, J. Comp. Neurol. 396 (1998) 51–63.

[40] F. Conti, L. Vitellaro Zuccarello, P. Barbaresi, A. Minelli, N.C. Brecha, M. Melone, Neuronal, glial, and epithelial localization of γ-aminobutyric acid transporter 2, a high-affinity γ-aminobutyric acid plasma membrane transporter, in the cerebral cortex and neighboring structures, J. Comp. Neurol. 409 (1999) 482–494.

[41] M.L. Cordero, J.G. Ortiz, G. Santiago, A. Negron, J.A. Moreira, Altered GABAergic and glutamatergic transmission in audiogenic seizure-susceptible mice, Mol. Neurobiol. 9 (1994) 253–258.

[42] J.L. Corey, N. Davidson, H.A. Lester, N.C. Brecha, M.W. Quick, Protein kinase C modulates the activity of a cloned γ-aminobutyric acid transporter expressed in Xenopus oocytes via regulated subcellular redistribution of the transporter, J. Biol. Chem. 269 (1994) 14759–14767.

[43] J.T. Coyle, S.J. Enna, Neurochemical aspects of the ontogenesis of GABAergic neurons in the rat brain, Brain Res. 111 (1976) 119–133.

[44] N.O. Dalby, GABA-level increasing and anticonvulsant effects of three different GABA uptake inhibitors, Neuropharmacology 39 (2000) 2399–2407.

[45] J. DeFelipe, Chandelier cells and epilepsy, Brain 122 (1999) 1807–1822.

[46] J. DeFelipe, I. Farinas, The pyramidal neuron of the cerebral cortex: morphological and chemical characteristics of the synaptic inputs, Prog. Neurobiol. 39 (1992) 563–607.

[47] J. DeFelipe, M.C. Gonzalez-Albo, Chandelier cell axons are immunoreactive for GAT-1 in the human neocortex, NeuroReport 9 (1998) 467–470.

[48] J. DeFelipe, S.H. Hendry, E.G. Jones, D. Schmechel, Variability in the termination of GABAergic chandelier cell axons in the monkey sensory-motor cortex, J. Comp. Neurol. 231 (1985) 364–384.

[49] J. DeFelipe, F. Conti, S.L. Van Eyck, T. Manzoni, Demonstration of glutamate-positive axon terminals forming asymmetrical synapses in the cat neocortex, Brain Res. 455 (1988) 162–165.

[50] J. DeFelipe, S.H.C. Hendry, E.G. Jones, Visualization of chandelier cell axons by parvalbumin immunoreactivity in monkey cerebral cortex, Proc. Natl. Acad. Sci. U. S. A. 86 (1989) 2093–2097.

[51] J. DeFelipe, M. Pilar, A. Fairen, E.G. Jones, Inhibitory synaptogenesis in mouse somatosensory cortex, Cereb. Cortex 7 (1997) 619–634.

[52] S.L. Deken, M.L. Beckman, L. Boos, M.W. Quick, Transport rates of GABA transporters: regulation by the N-terminal domain and syntaxin 1A, Nat. Neurosci. 3 (2000) 998–1003.

[53] S.L. Deken, D. Wang, M.W. Quick, Plasma membrane GABA transporters reside on distinct vesicles and undergo rapid regulated recycling, J. Neurosci. 23 (2003) 1563–1568.

[54] M.R. Del Bigio, The ependyma: a protective barrier between brain and cerebrospinal fluid, Glia 14 (1995) 1–13.

[55] J.A. Del Rio, E. Soriano, I. Ferrer, Development of GABA-immunoreactivity in the neocortex of the mouse, J. Comp. Neurol. 326 (1992) 501–526.

[56] M. Demarque, A. Represa, H. Becq, I. Khalilov, Y. Ben-Ari, L. Aniksztejn, Paracrine intercellular communication by a Ca²⁺- and SNARE-independent release of GABA and glutamate prior to synapse formation, Neuron 36 (2002) 1051–1061.

[57] E. De Robertis, H.S. Bennett, Submicroscopic vesicular component in the synapse, Fed. Proc. 13 (1954) 35.

[58] E. De Schutter, Cerebellar cortex: computation by extrasynaptic inhibition? Curr. Biol. 12 (2002) R363–R365.

[59] R. Dingledine, S.J. Korn, γ-Aminobutyric acid uptake and the termination of inhibitory synaptic potentials in the rat hippocampal slice, J. Physiol. 366 (1985) 387–409.

[60] J.S. Dittman, W.G. Regehr, Mechanism and kinetics of heterosynaptic depression at a cerebellar synapse, J. Neurosci. 17 (1997) 9048–9059.

[61] R. Domann, G. Hagemann, M. Kraemer, H.J. Freund, O.W. Witte, Electrophysiological changes in the surrounding brain tissue of photochemically induced cortical infarcts in the rat, Neurosci. Lett. 155 (1993) 69–72.

[62] M.J. During, K.M. Ryder, D.D. Spencer, Hippocampal GABA transporter function in temporal-lobe epilepsy, Nature 376 (1995) 174–177.

[63] M.M. Durkin, K.E. Smith, L.A. Borden, R.L. Weinshank, T.A. Branchek, E.L. Gustafson, Localization of messenger RNAs encoding three GABA transporters in rat brain: an in situ hybridization study, Mol. Brain Res. 33 (1995) 7–21.

[64] D. Engel, D. Schmitz, T. Gloveli, C. Frahm, U. Heinemann, A. Draguhn, Laminar difference in GABA uptake and GAT-1 expression in rat CA1, J. Physiol. 512 (1998) 643–6499.

[65] S.L. Erickson, D.A. Lewis, Postnatal development of parvalbumin-and GABA transporter-immunoreactive axon terminals in monkey prefrontal cortex, J. Comp. Neurol. 448 (2002) 186–202.

[66] J.E. Evans, A. Frostholm, A. Rotter, Embryonic and postnatal expression of four gamma-aminobutyric acid transporter mRNAs in the mouse brain and leptomeninges, J. Comp. Neurol. 376 (1996) 431–446.

[67] M. Fabri, T. Manzoni, Glutamate decarboxylase immunoreactivity in

corticocortical projecting neurons of rat somatic sensory cortex, Neuroscience 72 (1996) 435–448.

[68] R.S. Fisher, N.A. Buchwald, C.D. Hull, M.S. Levine, GABAergic basal forebrain neurons project to the neocortex: the localization of glutamic acid decarboxylase and choline acetyltransferase in feline corticopetal neurons, J. Comp. Neurol. 272 (1988) 489–502.

[69] D. Fitzpatrick, J.S. Lund, D.E. Schmechel, A.C. Towle, Distribution of GABAergic neurons and axon terminals in the macaque striate cortex, J. Comp. Neurol. 264 (1987) 73–91.

[70] T.F. Freund, V. Meskenaite, γ-Aminobutyric acid-containing basal forebrain neurons innervate inhibitory interneurons in the neocortex, Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 738–742.

[71] T.F. Freund, K.A.C. Martin, A.D. Smith, P. Somogyi, Glutamate decarboxylase-immunoreactive terminals of Golgi-impregnated axoaxonic cells and presumed basket cells in synaptic contacts with pyramidal neurons of the cat’s visual cortex, J. Comp. Neurol. 221 (1983) 263–278.

[72] J.-M. Fritschy, J. Paysan, A. Enna, H. Mohler, Switch in the expression of rat GABAA receptor subtypes during postnatal development: an immunocytochemical study, J. Neurosci. 14 (1994) 5302–5324.

[73] Y. Fueta, L.A. Vasilets, K. Takeda, M. Kawamura, W. Schwartz, Down-regulation of GABA-transporter function by hippocampal translation product: its possible role in epilepsy, Neuroscience 118 (2003) 371–378.

[74] A. Gadea, A.M. Lopez-Colome, Glial transporters for glutamate, glycine and GABA: II. GABA transporters, J. Neurosci. Res. 63 (2001) 461–468.

[75] K. Ganguly, A.F. Schinder, S.T. Wong, M. Poo, GABA itself promotes the developmental switch of neuronal GABAergic responses from excitation to inhibition, Cell 105 (2001) 521–532.

[76] H.L. Gaspany, W. Wang, G.B. Richerson, Carrier-mediated GABA release activates GABA receptors on hippocampal neurons, J. Neurophysiol. 80 (1998) 270–281.

[77] J. Gomez, M. Casado, C. Gimenez, C. Aragon, Inhibition of high-affinity γ-aminobutyric acid uptake in primary astrocyte cultures by phorbol esters and phospholipase C, Biochem. J. 275 (1991) 435–439.

[78] Y.A. Gonchar, P.B. Johnson, R.J. Weinberg, GABA-immunopositive neurons in rat neocortex with contralateral projections to S-I, Brain Res. 697 (1995) 27–34.

[79] S.F. Gonsalves, B. Twitchell, R.E. Harbaugh, P. Krogsgaard-Larsen, A. Schousboe, Anticonvulsant activity of intracerebroventricularly administered glial GABA uptake inhibitors and other GABA mimetics in chemical seizure models, Epilepsy Res. 4 (1989) 34–41.

[80] B. Granger, F. Tekai, A.M. Le Sourd, P. Rakic, J.P. Bourgeois, Tempo of neurogenesis and synaptogenesis in the primate cingulate mesocortex: comparison with the neocortex, J. Comp. Neurol. 360 (1995) 363–376.

[81] I. Gritti, L. Mainville, M. Mancia, B.E. Jones, GABAergic and other noncholinergic basal forebrain neurons, together with cholinergic neurons, project to mesocortex and isocortex in the rat, J. Comp. Neurol. 383 (1997) 163–177.

[82] T.R. Grossman, N. Nelson, Differential effect of pH on sodium binding by the various GABA transporters expressed in Xenopus oocytes, FEBS Lett. 527 (2002) 125–132.

[83] T.R. Grossman, N. Nelson, Effect of sodium lithium and proton concentrations on the electrophysiological properties of the four mouse GABA transporters expressed in Xenopus oocytes, Neurochem. Int. 43 (2003) 431–443.

[84] J. Guastella, N. Nelson, H. Nelson, L. Czyzyk, S. Keynan, M.C. Miedel, N. Davidson, H.A. Lester, B.I. Kanner, Cloning and expression of a rat brain GABA transporter, Science 249 (1990) 1303–1306.

[85] Y. Hachiya, S. Takashima, Development of GABAergic neurons and their transporter in human temporal cortex, Pediatr. Neurol. 25 (2001) 390–396.

[86] G. Hagemann, C. Redecker, T. Neumann-Haefelin, H.J. Freund,

O.W. Witte, Increased long-term potentiation in the surround of experimentally induced focal cortical infarction, Ann. Neurol. 44 (1997) 255–258.

[87] M. Hamann, D.J. Rossi, D. Attwell, Tonic and spillover inhibition of granule cells control information flow through cerebellar cortex, Neuron 33 (2002) 625–633.

[88] S.H.C. Hendry, R.K. Carder, Organization and plasticity of GABA neurons and receptors in monkey visual cortex, in: R.R. Mize, R.E. Marc, A.M. Sillito (Eds.), Progress in Brain Research, vol. 40, Elsevier, Amsterdam, 1992, pp. 477–502.

[89] S.H.C. Hendry, E.G. Jones, H.D. Schwark, J. Yang, Numbers and proportions of GABA immunoreactive neurons in different areas of monkey cerebral cortex, J. Neurosci. 7 (1987) 1503–1519.

[90] A.E. Herbison, S.J. Augood, S.X. Simonian, C. Chapman, Regulation of GABA transporter activity and mRNA expression by estrogen in rat preoptic area, J. Neurosci. 15 (1995) 8302–8309.

[91] T. Hirao, K. Morimoto, Y. Yamamoto, T. Watanabe, H. Sato, K. Sato, S. Sato, N. Yamada, K. Tanaka, H. Suwaki, Time-dependent and regional expression of GABA transporter mRNAs following amygdala-kindled seizures in rats, Mol. Brain Res. 54 (1998) 49–55.

[92] R.J. Hitzemann, H.H. Loh, High-affinity GABA and glutamate transport in developing nerve ending particles, Brain Res. 159 (1978) 29–40.

[93] C.R. Houser, S.H.C. Hendry, E.G. Jones, J.E. Vaughn, Morphological diversity of immunocytochemically identified GABA neurons in the monkey sensory-motor cortex, J. Neurocytol. 12 (1983) 617–638.

[94] C.R. Houser, S.H.C. Hendry, E.G. Jones, A. Peters, GABA neurons in the cerebral cortex, in: E.G. Jones, A. Peters (Eds.), Cerebral Cortex, Functional Properties of Cortical Cells, vol. 2, Plenum, New York, 1984, pp. 63–90.

[95] Y.H. Hua, J.H. Hu, W.J. Zhao, J. Fei, Y. Yu, X.G. Zhou, Z.T. Mei, L.H. Guo, Overexpression of γ-aminobutyric acid transporter subtype I leads to susceptibility to kainic acid-induced seizure in transgenic mice, Cell Res. 11 (2001) 61–67.

[96] C.A. Hubner, V. Stein, I. Hermans-Borgmeyer, T. Meyer, K. Ballanyi, T.J. Jentsch, Disruption of KCC2 reveals an essential role of K-Cl cotransport already in early synaptic inhibition, Neuron 30 (2001) 515–524.

[97] P.R. Huttenlocher, A.S. Dabholkar, Regional differences in synaptogenesis in human cerebral cortex, J. Comp. Neurol. 387 (1997) 167–178.

[98] P.R. Huttenlocher, C. de Courten, The development of synapses in striate cortex of man, Hum. Neurobiol. 6 (1987) 1–9.

[99] T. Ichinose, P.D. Lukasiewicz, GABA transporters regulate inhibition in the retina by limiting GABA(C) receptor activation, J. Neurosci. 22 (2002) 3285–3292.

[100] N. Ikegaki, N. Saito, M. Hashima, C. Tanaka, Production of specific antibodies against GABA transporter subtypes (GAT-1, GAT-2, GAT-3) and their application to immunocytochemistry, Mol. Brain Res. 26 (1994) 47–54.

[101] J.S. Isaacson, Spillover in the spotlight, Curr. Biol. (2000) R475–R477.

[102] J.S. Isaacson, J.M. Solis, R.A. Nicoll, Local and diffuse synaptic actions of GABA in the hippocampus, Neuron 10 (1993) 165–175.

[103] E.H. Jaffe, L. Figueroa, Glutamate receptor desensitization block potentiates the stimulated GABA release through external Ca²⁺-independent mechanisms from granule cells of olfactory bulb, Neurochem. Res. 26 (2001) 1177–1185.

[104] K. Jensen, C.-S. Chiu, I. Sokolova, H.A. Lester, I. Mody, GABA transporter-1 (GAT1) deficient mice: differential tonic activation of GABAA versus GABAB receptors in the hippocampus, J. Neurophysiol. 190 (2003) 2690–2701.

[105] J. Johnson, T.K. Chen, D.W. Rickman, C. Evans, N.C. Brecha, Multiple gamma-aminobutyric acid plasma membrane transporters (GAT-1, GAT-2, GAT-3) in the rat retina, J. Comp. Neurol. 375 (1996) 212–224.

[106] E.G. Jones, GABAergic neurons and their role in cortical plasticity, Cereb. Cortex 3 (1993) 361–372.

[107] F. Jursky, N. Nelson, Developmental expression of GABA transporters GAT1 and GAT4 suggests involvement in brain maturation, J. Neurochem. 67 (1996) 857–867.

[108] F. Jursky, N. Nelson, Developmental expression of the neurotransmitter transporter GAT3, J. Neurosci. Res. 55 (1999) 394–399.

[109] A. Kakee, H. Takanaga, T. Terasaki, M. Naito, T. Tsuruo, Y. Sugiyama, Efflux of a suppressive neurotransmitter, GABA, across the blood–brain barrier, J. Neurochem. 79 (2001) 110–118.

[110] B. Kanner, Structure and function of GABA reuptake systems, in: S.J. Enna, N.G. Bowery (Eds.), The GABA Receptors, Humana Press, Totowa, 1997, pp. 1–9.

[111] R. Kanthan, A. Shuaib, R. Griebel, H. Miyashita, Intracerebral human microdialysis. In vivo study of an acute focal ischemic model of the human brain, Stroke 26 (1995) 870–873.

[112] D.L. Kaufman, C.R. Houser, A.J. Tobin, Two forms of the gamma-aminobutyric acid synthetic enzyme glutamate decarboxylase have distinct intraneuronal distributions and cofactor interactions, J. Neurochem. 56 (1991) 720–723.

[113] T. Kietzmann, W. Knabe, R. Schmidt-Kastner, Hypoxia and hypoxia-inducible factor modulated gene expression in brain: involvement in neuroprotection and cell death, Eur. Arch. Psychiatry Clin. Neurosci. 251 (2001) 170–178.

[114] G.A. Kinney, W.J. Spain, Synaptically evoked GABA transporter currents in neocortical glia, J. Neurophysiol. 88 (2002) 2899–2908.

[115] Z.F. Kisvarday, A. Gulyas, D. Beroukas, J.B. North, I.W. Chubb, P. Somogyi, Synapses, axonal and dendritic patterns of GABA-immunoreactive neurons in human cerebral cortex, Brain 113 (1990) 793–812.

[116] A.R. Kriegstein, D.F. Owens, GABA may act as a self-limiting trophic factor at developing synapses, Sci. STKE 95 (2001) PE1.

[117] K. Krnjevic, Neurotransmitters in Cerebral Cortex: a general account, in: E.G. Jones, A. Peters (Eds.), Cerebral Cortex, Functional Properties of Cortical Cells, vol. 2, Plenum, New York, 1984, pp. 39–61.

[118] K. Krnjevic, Role of GABA in cerebral cortex, Can. J. Physiol. Pharm. 75 (1997) 439–451.

[119] K. Krnjevic, S. Schwartz, The action of γ-aminobutyric acid on cortical neurons, Exp. Brain Res. 3 (1967) 320–326.

[120] D.M. Kullmann, Spillover and synaptic cross talk mediated by glutamate and GABA in the mammalian brain, Prog. Brain Res. 125 (2000) 339–351.

[121] D.M. Kullmann, F. Asztely, Extrasynaptic glutamate spillover in the hippocampus: evidence and implications, Trends Neurosci. 21 (1997) 8–14.

[122] D.M.-K. Lam, J. Fei, X.Y. Zhang, A.C.W. Tam, L.H. Zu, F. Huang, S.C. King, L.H. Guo, Molecular cloning and structure of the human (GABATHG) GABA transport gene, Mol. Brain Res. 19 (1993) 227–232.

[123] A.S. LaMantia, The usual suspects: GABA and glutamate may regulate proliferation in the neocortex, Neuron 15 (1995) 1223–1225.

[124] J.M. Lauder, Neurotransmitters as growth regulatory signals: role of receptors and second messengers, Trends Neurosci. 16 (1993) 233–240.

[125] D.J. Laurie, W. Wisden, P.H. Seeburg, The distribution of thirteen GABA<sub>A</sub> receptor subunit mRNA in the rat brain: III. Embryonic and postnatal development, J. Neurosci. 12 (1992) 4151–4172.

[126] J.P. Leach, M.J. Brodie, Tiagabine, Lancet 351 (1998) 203–207.

[127] H. Lester, Listening to neurotransmitter transporters, Neuron 17 (1996) 807–810.

[128] G. Levi, M. Raiteri, Carrier-mediated release of neurotransmitters, Trends Neurosci. 16 (1993) 415–418.

[129] C.-S. Lin, M.A.L. Nicolelis, J.S. Schneider, J.K. Chapin, A major direct GABAergic pathway from zona incerta to neocortex, Science 248 (1990) 1553–1556.

[130] Q.-R. Liu, B. Lopez-Córcuera, S. Mandiyian, H. Nelson, N. Nelson,

Molecular characterization of four pharmacologically distinct γ-aminobutyric acid transporters in mouse brain, J. Biol. Chem. 268 (1993) 2106–2112.

[131] J.J. LoTurco, D.F. Owens, M.J.S. Heath, M.B.E. Davis, A.R. Kriegstein, GABA and glutamate depolarize progenitor cells and inhibit DNA synthesis, Neuron 15 (1995) 1287–1298.

[132] M.S. Luer, D.H. Rhoney, Tiagabine: a novel antiepileptic drug, Ann. Pharmacother. 32 (1998) 1173–1180.

[133] H.J. Luhmann, L.A. Mudrick-Donnon, T. Mittmann, U. Heinemann, Ischemia-induced long-term hyperexcitability in rat neocortex, Eur. J. Neurosci. 7 (1995) 180–191.

[134] S. Mager, J. Naeve, M. Quick, C. Labarca, N. Davidson, H. Lester, Steady states, charge movement, and rates for a cloned GABA transporter expressed in Xenopus oocytes, Neuron 10 (1993) 177–188.

[135] C. Matute, P. Streit, Monoclonal antibodies demonstrating GABA-like immunoreactivity, Histochemistry 86 (1986) 147–157.

[136] D.A. McCormick, Z. Wang, J. Huguenard, Neurotransmitter control of neocortical neuronal activity and excitability, Cereb. Cortex 3 (1993) 387–398.

[137] E. Meier, J. Drejer, A. Schousboe, GABA induces functionally active low-affinity GABA receptors on cultured cerebellar granule cells, J. Neurochem. 43 (1984) 1737–1744.

[138] B.S. Meldrum, A.G. Chapman, Basic mechanisms of gabitril (tiagabine) and future potential developments, Epilepsia 40 (Suppl. 9) (1999) S2–S6.

[139] M. Melone, P. Barbaresi, F. Conti, The localization of the GABA plasma membrane transporter GAT-3 in the human cerebral cortex: implications for the pathophysiology of cerebral ischemia (2003) submitted for publication.

[140] M. Melone, A. Cozzi, D.E. Pellegrini-Giampietro, F. Conti, Transient focal ischemia triggers neuronal expression of GAT-3 in the rat perilesional cortex, Neurobiol. Dis. 14 (2003) 120–132.

[141] K.D. Micheva, C. Beaulieu, Quantitative aspects of synaptogenesis in the rat barrel field cortex with special reference to the GABA circuitry, J. Comp. Neurol. 373 (1996) 340–354.

[142] A. Minelli, N.C. Brecha, C. Karschin, S. De Biasi, F. Conti, GAT-1, a high-affinity GABA plasma membrane transporter, is localized to neurons and astroglia in the cerebral cortex, J. Neurosci. 15 (1995) 7734–7746.

[143] A. Minelli, S. De Biasi, N.C. Brecha, L. Vitellaro Zuccarello, F. Conti, GAT-3, a high-affinity GABA plasma membrane transporter, is localized to astrocytic processes, and it is not confined to the vicinity of GABAergic synapses in the cerebral cortex, J. Neurosci. 16 (1996) 6255–6264.

[144] A. Minelli, P. Barbaresi, F. Conti, Postnatal development of high-affinity plasma membrane transporters GAT-2 and GAT-3 in the rat cerebral cortex, Dev. Brain Res. 142 (2003) 7–18.

[145] A. Minelli, L. Alonso-Nanclares, R.H. Edwards, J. DeFelipe, F. Conti, Postnatal development of the GABA vesicular transporter VGAT in rat cerebral cortex, Neuroscience 117 (2003) 337–346.

[146] S.J. Mitchell, R.A. Silver, GABA spillover from single inhibitory axons suppresses low-frequency excitatory transmission at the cerebellar glomerulus, J. Neurosci. 20 (2000) 8651–8658.

[147] T. Mittmann, H.J. Luhmann, R. Schmidt-Kastner, U.T. Eysel, H. Weigel, U. Heinemann, Lesion-induced transient suppression of inhibitory function in rat neocortex in vitro, Neuroscience 60 (1994) 891–906.

[148] H. Nelson, S. Mandiyan, N. Nelson, Cloning of the human GABA transporter, FEBS Lett. 269 (1990) 181–184.

[149] L. Nguyen, B. Malgrange, I. Breuskin, L. Bettendorff, G. Moonen, S. Belachew, J.M. Rigo, Autocrine/paracrine activation of the GABA<sub>A</sub> receptor inhibits the proliferation of neurogenic polysialylated neural cell adhesion molecule-positive (PSA-NCAM+) precursor cell from postnatal striatum, J. Neurosci. 23 (2003) 3278–3294.

[150] C. Nilsson, M. Lindvall-Axelsson, C. Owman, Neuroendocrine regulatory mechanisms in the choroid plexus-cerebrospinal fluid, Dev. Brain Res. 17 (1992) 109–138.

[151] A.W. O’Connell, G.B Fox, C. Kjoller, H.C. Gallagher, K.J. Murphy, J. Kelly, C.M. Regan, Anti-ischemic and cognition-enhancing properties of NNC-711, a gamma-aminobutyric acid reuptake inhibitor, Eur. J. Pharmacol. 424 (2001) 37–44.

[152] S. Orozco-Suarez, K.L. Brunson, A. Feria-Velasco, C.E. Ribak, Increased expression of gamma-aminobutyric acid transporter-1 in the forebrain of infant rats with corticotropin-releasing hormone-induced seizures but not in those with hyperthermia-induced seizures, Epilepsy Res. 42 (2000) 141–157.

[153] L.S. Overstreet, G.L. Westbrook, Synapse density regulates independence at unitary inhibitory synapses, J. Neurosci. 23 (2003) 2618–2626.

[154] F. Owens, A.R. Kriegstein, Is there more to GABA than synaptic inhibition? Nat. Rev., Neurosci. 3 (2002) 715–727.

[155] D.F. Owens, A.R. Kriegstein, Developmental neurotransmitters? Neuron 36 (2002) 989–991.

[156] D.F. Owens, L.H. Boyce, M.B.E. Davis, A.R. Kriegstein, Excitatory GABA responses in embryonic and neonatal cortical slices demonstrated by gramicidin perforated-patch recordings and calcium imaging, J. Neurosci. 16 (1996) 6414–6423.

[157] D.F. Owens, X. Liu, A.R. Kriegstein, Changing properties of GABA<sub>A</sub> receptor-mediated signaling during early neocortical development, J. Neurophysiol. 82 (1999) 570–583.

[158] G.E. Palade, S.L. Palay, Electron microscopic observations of interneuronal and neuromuscular synapses, Anat. Rec. 118 (1954) 335–336.

[159] S.L. Palay, Synapses in the central nervous system, J. Biophys. Biochem. Cytol. 2 (1956) 193–202 (Suppl.).

[160] P.R. Patrylo, D.D. Spencer, A. Williamson, GABA uptake and heterotransport are impaired in the dentate gyrus of epileptic rats and humans with temporal lobe sclerosis, J. Neurophysiol. 85 (2001) 1533–1542.

[161] A. Peters, K.M. Harriman, Different kinds of axon terminals forming symmetric synapses with the cell bodies and initial axon segments of layer II/III pyramidal cells: I. Morphometric analysis, J. Neurocytol. 19 (1990) 154–174.

[162] A. Peters, S.L. Palay, H. de F. Webster, The Fine Structure of the Nervous System, Oxford Univ. Press, New York, 1991.

[163] M. Pfeiffer, A. Draguhn, H. Meierkord, U. Heinemann, Effects of gamma-aminobutyric acid (GABA) agonists and GABA uptake inhibitors on pharmacosensitive and pharmaco-resistant epileptiform activity in vitro, Br. J. Pharmacol. 119 (1996) 569–577.

[164] J.-P. Pin, J. Bockaert, Two distinct mechanisms, differentially affected by excitatory aminoacids, trigger GABA release from fetal mouse striatal neurons in primary culture, J. Neurosci. 9 (1989) 648–656.

[165] M.O. Poulter, J.L. Barker, A.-M. O’Carrol, S.J. Lolait, L.C. Mahan, Differential and transient expression of GABA<sub>A</sub> receptor α-subunit mRNAs in the developing rat CNS, J. Neurosci. 12 (1992) 2888–2900.

[166] M.O. Poulter, J.L. Barker, A.-M. O’Carrol, S.J. Lolait, L.C. Mahan, Co-existent expression of GABA<sub>A</sub> receptor β2, β3 and γ2 subunit messenger RNAs during embryogenesis and early postnatal development of the rat central nervous system, Neuroscience 53 (1993) 1019–1033.

[167] M.W. Quick, J.L. Corey, N. Davidson, H.A. Lester, Second messengers, trafficking-related proteins, and amino acid residues that contribute to the functional regulation of the rat brain GABA transporter GAT-1, J. Neurosci. 17 (1997) 2967–2979.

[168] R. Radian, O.P. Ottersen, J. Storm-Mathisen, M. Castel, B.I. Kanner, Immunocytochemical localization of the GABA transporter in rat brain, J. Neurosci. 10 (1990) 1319–1330.

[169] V.K. Ramanathan, C.M. Brett, K.M. Giacomini, Na<sup>+</sup>-dependent γ-aminobutyric acid (GABA) transport in the choroid plexus of rabbit, Biochim. Biophys. Acta 1330 (1997) 94–102.

[170] P.B. Ramsay, M.R. Krigman, P. Morell, Developmental studies of the uptake of choline, GABA and dopamine by crude synaptosomal preparations after in vivo or in vitro lead treatment, Brain Res. 187 (1980) 383–402.

[171] A. Rasola, L.J.V. Galietta, V. Barone, G. Romeo, S. Bagnasco, Molecular cloning and functional characterization of a GABA/betaine transporter from human kidney, FEBS Lett. 373 (1995) 229–233.

[172] D.A. Redburn, D. Broome, J. Ferkany, S.J. Enna, Development of rat brain uptake and calcium-dependent release of GABA, Brain Res. 152 (1978) 511–519.

[173] C.E. Ribak, Aspinous and sparsely-spinous stellate neurons in the visual cortex of rat contain glutamic acid decarboxylase, J. Neurocytol. 7 (1978) 461–478.

[174] C.E. Ribak, A.B. Harris, J.E. Vaughn, E. Roberts, Inhibitory GABAergic nerve terminals decrease at sites of focal epilepsy, Science 205 (1979) 211–214.

[175] C.E. Ribak, R.M. Bradburne, A.B. Harris, A preferential loss of GABAergic inhibitory synapses in epileptic foci: a quantitative ultrastructural analysis of monkey neocortex, J. Neurosci. 2 (1982) 1725–1735.

[176] C. Rivera, J. Voipio, J.A. Payne, E. Ruusuvuori, H. Lahtinen, K. Lamsa, U. Pirvola, M. Saarma, K. Kaila, The K<sup>+</sup>/Cl<sup>−</sup> co-transporter KCC2 renders GABA hyperpolarizing during neuronal maturation, Nature 397 (1999) 251–255.

[177] D.J. Rossi, M. Hamann, Spillover-mediated transmission at inhibitory synapses promoted by high affinity 6 subunit GABA<sub>A</sub> receptors and glomerular geometry, Neuron 20 (1998) 783–795.

[178] A. Sarup, O.M. Larsson, T. Bolvig, B. Frolund, P. Krogsgaard-Larsen, A. Schousboe, Effects of 3-hydroxy-4-amino-4,5,6,7-tetrahydro-1,2-benzisoxazol (exo-THPO) and its N-substituted analogs on GABA transport in cultured neurons and astrocytes and by the four cloned mouse GABA transporters, Neurochem. Int. 43 (2003) 445–451.

[179] U. Sayin, S. Osting, J. Hagen, P. Rutecki, T. Sutula, Spontaneous seizures and loss of axo-axonic and axo-somatic inhibition induced by repeated brief seizures in kindled rats, J. Neurosci. 23 (2003) 2759–2768.

[180] M. Scanziani, GABA spillover activates postsynaptic GABA(B) receptor to control rhythmic hippocampal activity, Neuron 25 (2000) 673–681.

[181] K. Schiene, C. Bruehl, K. Zilles, M. Qu, G. Hagemann, M. Kraemer, O.W. Witte, Neuronal hyperexcitability and reduction of GABA<sub>A</sub>-receptor expression in the surround of cerebral phototrombosis, J. Cereb. Blood Flow Metab. 16 (1996) 906–914.

[182] A. Schousboe, Pharmacological and functional characterization of astrocytic GABA transport: a short review, Neurochem. Res. 25 (2000) 1241–1244.

[183] E.A. Schwartz, Calcium-independent release of GABA from isolated horizontal cells of the toad retina, J. Physiol. 323 (1982) 211–227.

[184] A. Semyanov, M.C. Walker, D.M. Kullmann, GABA uptake regulates cortical excitability via cell type-specific tonic inhibition, Nat. Neurosci. 6 (2003) 484–490.

[185] G.M. Shepherd, Foundations of the Neuron Doctrine, Oxford Univ. Press, New York, 1991.

[186] G.M. Shepherd, S.D. Erulkar, Centenary of the synapse: from Sherrington to the molecular biology of the synapse and beyond, Trends Neurosci. 20 (1997) 385–392.

[187] C.S. Sherrington, The central nervous system, in: M. Foster (Ed.), A Text-Book of Physiology, 7th ed., Part III, Macmillan, London, 1897.

[188] C.S. Sherrington, The Integrative Action of the Nervous System, Yale Univ. Press, New Haven, 1906.

[189] T.S. Sihra, D.G. Nicholls, γ-Aminobutyrate can be released exocytotically from guinea-pig cerebral cortical synaptosomes, J. Neurochem. 49 (1987) 261–267.

[190] A.M. Sillito, Functional considerations of the operation of GABAAergic inhibitory processes in the visual cortex, in: E.G. Jones, A. Peters (Eds.), Cerebral Cortex, Functional Properties of Cortical Cells, vol. 2, Plenum, New York, 1984, pp. 91–117.

[191] A.V. Silva, E.R. Sanabria, E.A. Cavalheiro, R. Spreafico, Alterations of the neocortical GABAergic system in the pilocarpine model

of temporal lobe epilepsy: neuronal damage and immunocytochemical changes in chronic epileptic rats, Brain Res. Bull. 58 (2002) 417–421.

[192] J.J. Sloper, P. Johnson, T.P.S. Powell, Selective degeneration of interneurons in the motor cortex of infant monkeys following controlled hypoxia: a possible cause of epilepsy, Brain Res. 198 (1980) 204–209.

[193] R.S. Sloviter, Decreased hippocampal inhibition and selective loss of interneurons in experimental epilepsy, Science 235 (1987) 73–76.

[194] P. Somogyi, Synaptic organization of GABAergic neurons and $G A B A_{A}$ receptors in the lateral geniculate nucleus and visual cortex, in: D.M.-K. Lam, C.D. Gilbert (Eds.), Neural Mechanisms of Visual Perception, Proceedings of the Retina Research Foundation, vol 2, MIT Press, Cambridge, 1989, pp. 35–62.

[195] P. Somogyi, K.A.C. Martin, Cortical circuitry underlying inhibitory processes in cat area 17, in: D. Rose, V.G. Dobson (Eds.), Models of the Visual Cortex, Wiley, Chichester, 1985, pp. 514–523.

[196] P. Somogyi, G. Tamás, R. Luján, E.H. Buhl, Salient features of synaptic organisation in the cerebral cortex, Brain Res. Rev. 6 (1998) 113–135.

[197] J.M. Soria, M. Valdeolmillos, Receptor-activated calcium signals in tangentially migrating cortical cells, Cereb. Cortex 12 (2002) 831–839.

[198] W. Soudijn, I. van Wijngaarden, The GABA transporter and its inhibitors, Curr. Med. Chem. 7 (2000) 1063–1079.

[199] R. Spreafico, L. Tassi, N. Colombo, M. Bramerio, C. Galli, R. Garbelli, A. Ferrario, G. Lo Russo, C. Munari, Inhibitory circuits in human dysplastic tissue, Epilepsia 4 (Suppl. 6) (2000) S168–S173.

[200] M. Sur, C.A. Leamey, Development and plasticity of cortical areas and networks, Nat. Rev., Neurosci. 2 (2001) 251–262.

[201] R.J. Sutch, C.C. Davies, N.G. Bowery, GABA release and uptake measured in crude synaptosomes from Genetic Absence Epilepsy Rats from Strasbourg (GAERS), Neurochem. Int. 34 (1999) 415–425.

[202] M. Swan, A. Najlerahim, R.E.B. Watson, J.P. Bennett, Distribution of mRNA for the GABA transporter GAT-1 in the rat brain: evidence that GABA uptake is not limited to presynaptic neurons, J. Anat. 185 (1994) 315–323.

[203] J. Taylor, P.R. Gordon-Weeks, Developmental changes in the calcium dependency of γ-aminobutyric acid release from isolated growth cones: correlation with growth cone morphology, J. Neurochem. 53 (1989) 834–843.

[204] J. Taylor, P.R. Gordon-Weeks, Calcium-independent γ-aminobutyric acid release from growth cones: role of γ-aminobutyric acid transport, J. Neurochem. 56 (1991) 273–280.

[205] S.M. Thompson, B.H. Gahwiler, Effects of the GABA uptake inhibitor tiagabine on inhibitory synaptic potentials in rat hippocampal slice cultures, J. Neurophysiol. 67 (1992) 1670–1698.

[206] R.D. Traub, J.G. Jefferys, M.A. Whittington, Fast Oscillations in Cortical Circuits, MIT Press, Cambridge, MA, 1999.

[207] S.R. Vincent, T. Hokfelt, L.R. Skirboll, J.Y. Wu, Hypothalamic gamma-aminobutyric acid neurons project to the neocortex, Science 220 (1983) 1309–1311.

[208] S.L. Vincent, L. Pabreza, F.M. Benes, Postnatal maturation of GABA-immunoreactive neurons of rat medial prefrontal cortex, J. Comp. Neurol. 355 (1995) 81–92.

[209] K.E. Vogt, R.A. Nicoll, Glutamate and gamma-aminobutyric acid mediate a heterosynaptic depression at mossy fiber synapses in the hippocampus, Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 1118–1122.

[210] C. Wang, C. Shimizu-Okabe, K. Watanabe, A. Okabe, H. Matsuzaki, T. Ogawa, N. Mori, A. Fukuda, K. Sato, Developmental changes in KCC1, KCC2 and NKCC1 mRNA expressions in the rat brain, Dev. Brain Res. 139 (2002) 59–66.

[211] H.S. White, A. Sarup, T. Bolvig, A.S. Kristensen, G. Petersen, N. Nelson, D.S. Pickering, O.M. Larsson, B. Frolund, P. Krogsbøll-Larsen, A. Schousboe, Correlation between anticonvulsant activity and inhibitory action on glial gamma-aminobutyric acid uptake of the highly selective mouse gamma-aminobutyric acid transporter 1 inhibitor 3-hydroxy-4-amino-4,5,6,7-tetrahydro-1,2-benzisoxazole and its $N$-alkylated analogs, J. Pharmacol. Exp. Ther. 302 (2002) 636–644.

[212] T.L. Whitworth, M.W. Quick, Substrate-induced regulation of gamma-aminobutyric acid transporter trafficking requires tyrosine phosphorylation, J. Biol. Chem. 276 (2001) 42932–42937.

[213] F.A. Wilson, S.P. O'Scalaidhe, P.S. Goldman-Rakic, Functional synergism between putative gamma-aminobutyrate-containing neurons and pyramidal neurons in prefrontal cortex, Proc. Natl. Acad. Sci. U. S. A. (1994) 4009–4013.

[214] O.W. Witte, G. Stoll, Delayed and remote effects of focal cortical infarctions: secondary damage and reactive plasticity, Adv. Neurol. 73 (1997) 207–227.

[215] J.R. Wolff, H. Bottcher, T. Zetsche, W.H. Oertel, B.M. Chromwall, Development of GABAergic neurons in rat visual cortex as identified by glutamate decarboxylase-like immunoreactivity, Neurosci. Lett. 47 (1984) 207–212.

[216] P.T.-H. Wong, E.G. McGeer, Postnatal changes of GABAergic and glutamatergic parameters, Brain Res. 1 (1981) 519–529.

[217] Y. Wu, W. Wang, G.B. Richerson, GABA transaminase inhibition induces spontaneous and enhances depolarization-evoked GABA efflux via reversal of the GABA transporter, J. Neurosci. 21 (2001) 2630–2639.

[218] Y. Wu, W. Wang, G.B. Richerson, Vigabatrin induces tonic inhibition via GABA transporter reversal without increasing vesicular GABA release, J. Neurophysiol. 89 (2003) 2021–2034.

[219] Y. Xia, M.S. Poosch, C.J. Whitty, G. Kapatos, M.J. Bannon, GABA transporter mRNA: in vitro expression and quantitation in neonatal rat and postmortem human brain, Neurochem. Int. 22 (1993) 263–270.

[220] W.C. Xu, Y. Yi, L. Qiu, A. Shuaib, Neuroprotective activity of tiagabine in a focal embolic model of cerebral ischemia, Brain Res. 874 (2000) 75–77.

[221] A. Yamauchi, S. Uchida, H.M. Kwon, A.S. Preston, R.B. Robey, A. Garcia-Perez, M.B. Burg, J.S. Handler, Cloning of a $\mathrm{Na}^{+}$- and $\mathrm{Cl}^{-}$ dependent betaine transporter that is regulated by hypertonicity, J. Biol. Chem. 267 (1992) 649–652.

[222] X.-X. Yan, W.A. Cariaga, C.E. Ribak, Immunoreactivity for GABA plasma membrane transporter, GAT-1, in the developing rat cerebral cortex: transient presence in the somata of neocortical and hippocampal neurons, Dev. Brain Res. 99 (1997) 1–19.

[223] Y. Yang, C.X. Wang, T. Jeerakathil, A. Shuaib, Dose-dependent neuroprotection with tiagabine in a focal cerebral ischemia model in rat, NeuroReport 11 (2000) 2307–2311.

[224] M. Yasumi, K. Sato, S. Shimada, M. Nishimura, M. Tohyama, Regional distribution of GABA transporter 1 (GAT1) mRNA in the rat brain: comparison with glutamic acid decarboxylase ${ }_{67}$ ($\mathrm{GAD}_{67}$) mRNA localization, Mol. Brain Res. 44 (1997) 205–218.

[225] N. Zecevic, P. Rakic, Synaptogenesis in monkey somatosensory cortex, Cereb. Cortex 1 (1991) 510–523.
